Post Hoc Evidence for an Additive Effect of Memantine and Donepezil: Consistent Findings from DOMINO-AD Study and...

Area of Science:

• Neuroscience
• Pharmacology
• Geriatrics

Background:

• Previous trials indicated memantine-cholinesterase inhibitor combination therapy is superior for moderate to severe Alzheimer's disease (AD).
• A recent study reported no additional benefit of add-on memantine compared to donepezil alone.
• This discrepancy necessitates re-evaluation of existing data.

Purpose of the Study:

• To re-evaluate the DOMINO study results using standard statistical tools.
• To apply DOMINO study statistical models to pooled data from memantine trials.
• To explore the robustness of the DOMINO study's primary findings in moderate to severe AD patients.

Main Methods:

• Post hoc analysis of the DOMINO study (N=295).
• Pooled analysis of four randomized trials (N=1417) of memantine in moderate to severe AD.
• Utilized common statistical tools and models from the DOMINO study.

Main Results:

• Re-assessment of the DOMINO study showed benefits of add-on memantine to donepezil.
• Pooled analysis of memantine trials also indicated benefits across multiple clinical domains.
• Both analyses support the efficacy of combination therapy.

Conclusions:

• The DOMINO study results do not contradict previous findings on memantine-cholinesterase inhibitor combination therapy.
• Combination therapy with memantine and donepezil demonstrates benefits in patients with moderate to severe AD.
• The findings support the continued use of memantine in combination with cholinesterase inhibitors for AD management.